Comparison of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Antibody Response by Different Vaccine Combinations
Open Access
- 1 January 2024
- journal article
- research article
- Published by Kare Publishing in Journal of Clinical Practice and Research
- Vol. 46 (4) , 347-353
Abstract
Objective: Various types and combinations of vaccines have been utilized at different time intervals due to the variable availability of vaccines in many countries during the Coronavirus Disease 2019 (COVID-19) pandemic. Most current vaccine administrations involve a series of primary doses followed by a homologous booster dose. This study aimed to examine the antibody levels after the BNT162b2 or CoronaVac vaccine was administered as a booster dose to volunteers who received two doses of CoronaVac and to identify the ideal vaccination combination. Materials and Methods: This cross-sectional study included 254 participants. The groups consisted of volunteers who received two doses of CoronaVac, those who received two doses of BNT162b2, those who received two doses of CoronaVac plus one dose of BNT162b2, and finally, those who received three doses of CoronaVac. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) specific spike (S) Immunoglobulin G (IgG) levels were measured by electrochemiluminescence method on Roche COBAS 8000 series using Anti-SARS-CoV-2 S kit. Results: Antibody levels after three doses of CoronaVac were found to be lower compared to after two doses of CoronaVac + one dose BNT162b2 (p<0.001). IgG responses after three doses of the CoronaVac vaccine (two primary + one booster dose) were lower than those after two doses of BNT162b2 (p<0.001). Conclusion: The use of a heterogeneous booster dose due to problems in vaccine supply may be a good alternative to the homologous approaches applied so far.Keywords
This publication has 29 references indexed in Scilit:
- Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variantsNature Communications, 2022
- Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised studyThe Lancet, 2022
- Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort studyThe Lancet Respiratory Medicine, 2021
- Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccinationNature, 2021
- Heterologous ChAdOx1 nCoV-19 and mRNA-1273 VaccinationNew England Journal of Medicine, 2021
- Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialThe Lancet, 2021
- Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in TurkeyThe Lancet, 2021
- Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trialThe Lancet, 2021
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance dataThe Lancet, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021